AR
Arterra Bioscience
ARBS.MI · MIL
3.06 € +0.00% (+0.00 €)
1M +3.03%
Market Cap 19.9M €
P/E Ratio 9.93x
Div. Yield 4.90%
ROE 17.34%
Bulios Fair Price
2.17 €
29.1% downside
Current Price
3.06 €
Undervalued Fair Value Overvalued
According to Bulios Fair Price, ARBS.MI is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
5/9Valuation
73 /100
Cheap P/E 9.93x
EV/EBITDA 21.37x
PEG 0.20x
Growth
61 /100
Stable EPS growth 12.62%
Rev. growth 8.99%
Book val. growth 6.33%
Profitability
70 /100
Strong Gross margin 15.87%
Net margin 43.15%
FCF margin 33.10%
Quality
52 /100
Average ROIC 4.31%
ROE 17.34%
Asset turnover 0.32x
Debt
100 /100
Low Debt/Equity 0.02x
Current ratio 7.74x
Net debt/EBITDA -1.23x
Stability
77 /100
Stable Beta 0.64x
Rev. volatility 16.15%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about ARBS.MI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Maria Gabriella Colucci
Employees
36
Headquarters
Napoli